Status:
COMPLETED
The Performance of Patient Support Program in Early Stage Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
The purpose of this study is to compare the 1-year adherence to upfront adjuvant AI for postmenopausal, early stage breast cancer in the two observational arms; Standard Treatment and Standard Treatme...
Eligibility Criteria
Inclusion
- Provide signed and dated written Informed Consent
- Have been taking upfront AI adjuvant therapy in line with current SmPC
- Be capable of completing drug intake by herself
- Be capable of understanding Chinese
Exclusion
- Upfront adjuvant hormonal therapy by an AI to which upfront adjuvant indication has not been granted by SFDA
- Upfront adjuvant AI medication which has exceeded over eight weeks
- Previous adjuvant hormonal therapy for breast cancer lasting over 8 weeks other than AI
- Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
524 Patients enrolled
Trial Details
Trial ID
NCT00769080
Start Date
September 1 2008
End Date
October 1 2010
Last Update
November 29 2011
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, Beijing Municipality, China
2
Research Site
Chongqing, Chongqing Municipality, China
3
Research Site
Guangzhou, Guangdong, China
4
Research Site
Nanning, Guangxi, China